Video

Alasdair Coles, MD

Publish date: May 7, 2015

Prof. Coles provides four-year follow-up data from the CARE-MS I and CARE-MS II trials, which showed the durable effect of alemtuzumab.


 

References

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Can FLAIR MRI Show Treatment Efficacy?
MDedge Neurology
Using the GAD-7 Scale in Multiple Sclerosis Patients
MDedge Neurology
Concurrent Autoimmune Diseases in MS
MDedge Neurology
Does Pharmacy-Directed Treatment Management Improve Care?
MDedge Neurology
MSC Consensus Paper on DMTs in MS
MDedge Neurology
Robert Fox, MD
MDedge Neurology
Peginterferon beta-1a MS data show positive early and long-term results
MDedge Neurology
AAN: Study supports safety of fingolimod for MS
MDedge Neurology
Stacey Cofield, PhD
MDedge Neurology
Amber Salter, PhD, MPH
MDedge Neurology